Does zinc help hair loss?
Zinc helps when hair loss comes from a real lack of zinc: in published case reports, the loss stopped or improved once zinc was given, though we found no controlled trial even here. Without a known deficiency, the evidence is thin and conflicting. In alopecia areata, a 1981 placebo-controlled trial is reported to have found no improvement, while a 2012 one, which a third of its patients did not finish, reported more complete regrowth on zinc; in a 2017 trial in 73 women with hair loss, zinc did the least for hair density of four treatments. The American Academy of Dermatology says to take zinc only when a blood test shows a deficiency, as with normal levels a supplement can be harmful. Europe's adult upper limit is 25 mg a day from all sources, set to protect copper levels, which 50 mg or more a day for weeks can lower.
When zinc deficiency is the cause
A 2019 review calls hair loss "a well-known sign" of established zinc deficiency, with hair regrowing once zinc is given. For this it cites a review of skin signs of nutritional deficiency in children and one case report: a four-year-old girl whose hair loss stopped within three weeks of starting zinc and a changed diet. In a 2012 report of five patients whose shedding was linked to zinc deficiency, hair loss was "cured or improved" on zinc in all five. In acrodermatitis enteropathica, a rare condition usually linked to inherited or acquired zinc deficiency, a 2025 review of 231 published cases in children found hair loss in 88 of the 209 whose other symptoms were recorded, but not how hair responded to zinc. These are case reports and case series; we found no controlled trial in deficient people, and the 2019 review calls for large placebo-controlled trials in people with both a deficiency and hair loss.
Who lacks zinc, and whether to test
The NIH Office of Dietary Supplements lists those most likely to lack zinc: people with bowel diseases such as Crohn's disease or ulcerative colitis, or weight-loss surgery that removed part of the gut; vegetarians and vegans; pregnant and breastfeeding women; and people with alcohol use disorder. Thiazide diuretics raise urinary zinc loss, and the 2019 review adds anorexia nervosa, cystic fibrosis and cereal-heavy, low-meat diets. Blood zinc, the usual test, varies with age, sex, time of day, infection and weight loss. For pattern hair loss and telogen effluvium, the 2019 review does not recommend screening for zinc, and its plain-language summary finds "insufficient data to recommend zinc" supplements "in cases of deficiency", which we read as low zinc found in a work-up, not established deficiency. A 2025 Israeli study of 23,975 adults tested for zinc found a median of 96 µg/dL in the 2,279 with either diagnosis and 99 in those tested for other reasons; its authors judged the gap clinically insignificant and suggest not testing zinc when investigating hair loss.
Trials in pattern hair loss and shedding
We found one published randomised trial of oral zinc alone in common hair loss. In 2017, a trial funded by Isfahan University of Medical Sciences gave 73 women with hair loss zinc (50 mg a day, twice Europe's adult upper limit), vitamin B5, both, or minoxidil solution for four months, with no placebo group and the women aware of their treatment; the paper does not report their zinc levels. Zinc alone gave the smallest gain in hair density of the four, and minoxidil the largest. A 2023 systematic review of supplements in people without a known deficiency, citing this trial and two in alopecia areata, listed zinc among products whose highest-quality studies showed a "potential benefit", to be read in the context of each study's design. The 2017 European guideline on pattern hair loss found the evidence on zinc "inadequate", as it had been studied only with other agents.
Zinc in alopecia areata
A 2025 meta-analysis of 10 studies found lower blood zinc in people with alopecia areata than in people without, though its authors say wide variation between studies weakens the result. Two double-blind placebo-controlled trials disagree. A 2017 review describes the first, from 1981, as 42 patients given zinc or a placebo for three months: no improvement, although blood and hair zinc rose on zinc. In the second, from Iraq in 2012, 100 people with patchy alopecia areata and normal average blood zinc took zinc or a placebo for three months, then swapped; of the 67 who finished, hair had fully regrown at three months in 22 of 37 on zinc and 3 of 30 on placebo. A 2019 systematic review of randomised trials of whole-body treatments, citing the first trial but not the second, found the evidence does not support oral zinc sulphate. In a 2009 study with no comparison group, 9 of 15 people with alopecia areata and low zinc had regrowth rated positive after 12 weeks of zinc, which the authors note was not statistically significant.
Zinc shampoo
Zinc pyrithione, used in shampoos against seborrhoeic dermatitis, is applied to the scalp rather than swallowed. In a 2003 trial, 200 men with pattern hair loss used a 1% zinc pyrithione shampoo daily, a placebo shampoo, 5% minoxidil solution, or minoxidil with the shampoo, for 26 weeks. The zinc pyrithione shampoo raised hair counts significantly more than placebo, by slightly less than half as much as minoxidil, a gain the authors call modest and sustained. In overall ratings, its benefit tended to be visible only to the investigator, not to the men. Five of the seven authors were affiliated with Procter & Gamble. The European guideline notes that seborrhoeic dermatitis is common in pattern hair loss and may make hair loss worse, so the shampoo's own effect is hard to judge, and it makes no recommendation for or against.
Safety and upper limits
EFSA, Europe's food safety authority, gives an upper limit for adults, pregnancy included, of 25 mg of zinc a day from all sources: half of 50 mg, the intake at which small, short studies found no harm to copper status. The US upper limit is 40 mg. The NIH says 50 mg or more a day, taken for weeks, can interfere with copper absorption and lower copper status. Prolonged intakes of 50 to 300 mg a day have been linked to low blood copper, anaemia and low white blood cells, many of them like the changes of copper deficiency, though the opinion behind EFSA's limit says such overt effects appear only above 150 mg a day for long periods. The product information for two French zinc medicines lists the same effects in reported overdoses. Zinc adds up across products: a 2025 report found it in all three hair supplements and all three women's multivitamins it took from Amazon's best-seller lists.
Zinc on EU labels and as a French medicine
Under EU law, a food or supplement that is at least a source of zinc may say that zinc "contributes to the maintenance of normal hair". The claim says nothing about hair growth or hair loss. In France, zinc is also sold as a medicine. Two zinc gluconate capsules in the public medicines database, each with 15 mg of zinc, are authorised for mild to moderate inflammatory acne and for acrodermatitis enteropathica, not for hair loss. They need no prescription, and the HAS rated their clinical benefit low in acne and moderate in acrodermatitis enteropathica.
Related questions
Sources
- The Role of Vitamins and Minerals in Hair Loss: A Review · Dermatology and Therapy, 2019 · PMID 30547302
- Diffuse alopecia in a child due to dietary zinc deficiency · Skinmed, 2007 · PMID 17618180
- Acrodermatitis enteropathica in the pediatric population: a literature review of real-world studies · Frontiers in Nutrition, 2025 · PMID 40584104
- Oral zinc therapy for zinc deficiency-related telogen effluvium · Dermatologic Therapy, 2012 · PMID 22741940
- Hair Loss and Zinc Deficiency: A Cross-Sectional Study · Healthcare, 2025 · PMID 41302353
- Zinc - Health Professional Fact Sheet · NIH Office of Dietary Supplements, 2026
- Hair loss: Diagnosis and treatment · American Academy of Dermatology, 2022
- Comparing the Effects of Zinc Sulfate, Calcium Pantothenate, Their Combination and Minoxidil Solution Regimens on Controlling Hair Loss in Women: A Randomized Controlled Trial · Journal of Research in Pharmacy Practice, 2017 · PMID 28616431
- Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss: A Systematic Review · JAMA Dermatology, 2023 · PMID 36449274
- S3 - European Dermatology Forum Guideline for the Treatment of Androgenetic Alopecia in Women and in Men · European Dermatology Forum, 2017
- Association Between Serum Trace Elements Level and Alopecia Areata: A Systematic Review and Meta-Analysis · Journal of Cosmetic Dermatology, 2025 · PMID 39739356
- Oral zinc sulphate in alopacia areata–a double blind trial · British Journal of Dermatology, 1981 · PMID 7016162
- The role of micronutrients in alopecia areata: A Review · American Journal of Clinical Dermatology, 2017 · PMID 28508256
- Oral Zinc Sulphate in Treatment of Alopecia Areata (Double Blind; Cross-Over Study) · Journal of Clinical & Experimental Dermatology Research, 2012
- Systemic treatments for alopecia areata: A systematic review · Australasian Journal of Dermatology, 2019 · PMID 30191561
- The Therapeutic Effect and the Changed Serum Zinc Level after Zinc Supplementation in Alopecia Areata Patients Who Had a Low Serum Zinc Level · Annals of Dermatology, 2009 · PMID 20523772
- The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial · British Journal of Dermatology, 2003 · PMID 12932243
- Overview on Tolerable Upper Intake Levels as derived by the Scientific Committee on Food (SCF) and the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) · European Food Safety Authority, 2025
- Tolerable Upper Intake Levels for Vitamins and Minerals · European Food Safety Authority, 2006
- Supratherapeutic vitamin D with a hair nutraceutical: A case report · JAAD Case Reports, 2025 · PMID 40791753
- Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health · European Commission, 2012
- RUBOZINC 15 mg, gélule · Base de données publique des médicaments (ANSM), 2023
- EFFIZINC 15 mg, gélule · Base de données publique des médicaments (ANSM), 2018
Checked against its sources on 2026-11-01, by us, not by a doctor. A research register, not medical advice: talk to a dermatologist about your own case. See why we're not doctors.